T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy
These findings demonstrate that FuNV<sub>CAR</sub> enables functional in vivo CAR-T cell generation and sustained disease modification in experimental arthritis. FuNV<sub>CAR</sub> represents a mechanistically distinct and scalable platform for CAR-T-based immunotherapy in RA and other B cell-driven autoimmune diseases.
Authors
- Keming Lin
- Yuncheng Zeng
- Zhen Xiao
- Shikun Zhou
- Peilong Lai
- Congfei Xu
- Shujie Liang
- Gui Zhao
- Yiqun Sun
Institutions
- Guangdong Academy of Medical Sciences (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Biomarker Research
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1186/s40364-026-00905-3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00